Codexis, Inc. and its peers
1 companies side by side: each figure with its date and source, its rank in the group and its percentile in its sector and country.
Companies in the group
Up to 12. Remove or re-base from the table's column heads.
Keep this group
Save it for yourself or, in a team, for everyone in it.
Suggested peers of Codexis, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Perspective Therapeutics, Inc.CATX · 🇺🇸 USASame industry: Biotechnology · Similar size: $141 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $141 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Inovio Pharmaceuticals, Inc.INO · 🇺🇸 USASame industry: Biotechnology · Similar size: $144 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $144 M (Oct 30, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Compass Therapeutics, Inc.CMPX · 🇺🇸 USASame industry: Biotechnology · Similar size: $137 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $137 M (Oct 29, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- TuHURA Biosciences, Inc. NVHURA · 🇺🇸 USASame industry: Biotechnology · Similar size: $135 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $135 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Voyager Therapeutics, Inc.VYGR · 🇺🇸 USASame industry: Biotechnology · Similar size: $134 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $134 M (Oct 14, 2026) · revenue $40 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Armata Pharmaceuticals, Inc.ARMP · 🇺🇸 USASame industry: Biotechnology · Similar size: $130 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $130 M (Oct 28, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Spruce Biosciences, Inc.SPRB · 🇺🇸 USASame industry: Biotechnology · Similar size: $130 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $130 M (Oct 26, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Sutro Biopharma, Inc.STRO · 🇺🇸 USASame industry: Biotechnology · Similar size: $155 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $155 M (Oct 26, 2026) · revenue $102 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Nkarta, Inc.NKTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $125 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $125 M (Oct 22, 2026)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Humacyte, Inc.HUMA · 🇺🇸 USASame industry: Biotechnology · Similar size: $125 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $125 M (Oct 28, 2026) · revenue $2 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Anavex Life Sciences Corp.AVXL · 🇺🇸 USASame industry: Biotechnology · Similar size: $123 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $123 M (Oct 26, 2026)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Foghorn Therapeutics Inc.FHTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $123 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $123 M (Oct 28, 2026) · revenue $31 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Codexis, Inc.base CDXS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|
| Size | ||
| Market cap (Better neither way: ranked highest first) | $140 MOct 26, 2026 · Market dataonly one with it | $140 M— |
| Revenue (Better neither way: ranked highest first) | $70 MFY2025 · SEConly one with it | $70 M— |
| Net income (Higher is better) | $-44 MFY2025 · SEConly one with it | $-44 M— |
| Employees (Better neither way: ranked highest first) | 261As on 2021 · Profileonly one with it | 261— |
| Growth | ||
| Revenue growth (Higher is better) | +18.6%FY2025 · SEConly one with it66th77th | +18.6%— |
| Revenue growth, 3 years a year (Higher is better) | -20.2%FY2025 · SEConly one with it6th4th | -20.2%— |
| Margins and returns | ||
| Gross margin (Higher is better) | 86.7%FY2025 · SEConly one with it88th95th | 86.7%— |
| Operating margin (Higher is better) | -59.3%FY2025 · SEConly one with it29th14th | -59.3%— |
| Net margin (Higher is better) | -62.5%FY2025 · SEConly one with it28th13th | -62.5%— |
| Free cash flow margin (Higher is better) | -33.9%FY2025 · SEConly one with it31st14th | -33.9%— |
| Return on equity (Higher is better) | -74.9%FY2025 · SEConly one with it32nd13th | -74.9%— |
| Valuation | ||
| Price to sales (Better neither way: ranked highest first) | 1.6×price Oct 26, 2026 · Market dataonly one with it27th41st | 1.6×— |
| Price to book (Better neither way: ranked highest first) | 2.8×price Oct 26, 2026 · Market dataonly one with it47th59th | 2.8×— |
| Free cash flow yield (Higher is better) | -17.0%price Oct 26, 2026 · Market dataonly one with it35th16th | -17.0%— |
| Financial strength | ||
| Debt to equity (Lower is better) | 0.8×FY2025 · SEConly one with it69th60th | 0.8×— |
| Piotroski F-score (Higher is better) | 4 of 9FY2025 · SEConly one with it | 4.0 of 9— |
| Scorecard | ||
| Scorecard (Higher is better) | 7 of 22FY2025 · Scorecardonly one with it | 32% passed— |
| Valuation checks (Higher is better) | 2 of 5FY2025 · Scorecardonly one with it | 40% passed— |
| Growth checks (Higher is better) | 1 of 6FY2025 · Scorecardonly one with it | 17% passed— |
| Profitability checks (Higher is better) | 1 of 5FY2025 · Scorecardonly one with it | 20% passed— |
| Financial health checks (Higher is better) | 3 of 5FY2025 · Scorecardonly one with it | 60% passed— |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecardonly one with it | 0% passed— |
| Ownership | ||
| Held by institutions (Better neither way: ranked highest first) | 68.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it | 68.6%— |
| Institutions holding (Better neither way: ranked highest first) | 1302026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it | 130— |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | -8.3 pp2026-Q2 against 2026-Q1 · 13Fonly one with it | -8.3 pp— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Codexis, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Codexis, Inc. | -59.3%FY2025 | 29th percentile in Healthcaremedian -7.7%, 674 companies | 14th percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
Ranks need two fiscal years with the figure for at least two of these companies.
| Fiscal year | Codexis, Inc. |
|---|---|
| 2025 | $70 MSEC |
| 2024 | $59 MSEC |
| 2023 | $70 MSEC |
| 2022 | $139 MSEC |
| 2021 | $105 MSEC |
| 2020 | $69 MSEC |
| 2019 | $68 MSEC |
| 2018 | $61 MSEC |
| 2017 | $50 MSEC |
| 2016 | $49 MSEC |
| 2015 | $42 MSEC |
| 2014 | $35 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.